Highlights from Recursion's Era of TechBio Event with Pharma & Investment Leaders at JPM 2025

Our "Era of TechBio" event at the San Francisco Mint during the J.P. Morgan Healthcare Conference was a reminder of how far we have come -- building the data, the models, and the lab automation to bring us to this inflection point – and of what we need to do to accelerate the AI-enabled future of drug discovery even further.

With thought leaders from investment, pharma and academia, we set out to answer the question asked by Chief R&D and Chief Commercial Officer Najat Khan, PhD at the onset of the event, “Where is the era of TechBio today?”

▪️ “The impossible,” said Dean Y. Li, MD, PhD of Merck Research Laboratories, “is maybe just becoming probable.”

▪️ Kimberly Powell of NVIDIA noted that digital intelligence has the capacity to “advance science in incredible ways.”

▪️ Tony Kim of BlackRock pointed to the importance of end-to-end “horizontal platforms” in this new era.

▪️ Alex Gorsky, formerly of Johnson & Johnson, reminded the audience that we must always be focused on not just the technology, but “the value we are providing.”

▪️ In a fireside chat with Natasha Loder of The Economist, CRISPR pioneer
Jennifer Doudna talked about the incredible breakthroughs that are becoming possible as we begin to aggregate disparate data types.

▪️ Closing out the event, co-founder and CEO Chris Gibson encouraged the audience to “go after big swings,” adding: “We are an industry with so much potential for impact, but there’s so much more we can do.”
Captions are auto generated